|
[1]
|
Sung, H., Siegel, R.L., Laversanne, M., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Restifo, N.P., Dudley, M.E. and Rosenberg, S.A. (2012) Adoptive Immunotherapy for Cancer: Harnessing the T Cell Response. Nature Reviews Immunology, 12, 269-281. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
潘玉竹, 曹政. 肿瘤过继性细胞治疗的研究进展[J]. 免疫学杂志, 2020, 36(1): 86-92.
|
|
[4]
|
Gross, G., Waks, T. and Eshhar, Z. (1989) Expression of Immunoglobulin-T-Cell Receptor Chimeric Molecules as Functional Receptors with Antibody-Type Specificity. Proceedings of National Academy of Sciences of the United States of America, 86, 10024-10028. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Hong, M., Clubb, J.D. and Chen, Y.Y. (2020) Engineering CAR-T Cells for Next-Generation Cancer Therapy. Cancer Cell, 38, 473-488. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Holstein, S.A. and Lunning, M.A. (2020) CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress. Clinical Pharmacology & Therapeutics, 107, 112-122. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Fraietta, J.A., Lacey, S.F., Orlando, E.J., et al. (2018) Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy of Chronic Lymphocytic Leukemia. Nature Medicine, 24, 563-571. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Hofmann, S., Schubert, M.-L., Wang, L., et al. (2019) Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML). Journal of Clinical Medicine, 8, 200. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Gagelmann, N., Riecken, K., Wolschke, C., et al. (2020) Development of CAR-T Cell Therapies for Multiple Myeloma. Leukemia, 34, 2317-2332. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Mikkilineni, L. and Kochenderfer, J.N. (2021) CAR T Cell Therapies for Patients with Multiple Myeloma. Nature Reviews Clinical Oncology, 18, 71-84. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Sengupta, R. and Honey, K. (2020) AACR Cancer Progress Report 2020: Turning Science into Lifesaving Care. Clinical Cancer Research, 26, 5055. [Google Scholar] [CrossRef]
|
|
[12]
|
Brudno, J.N., Lam, N., Vanasse, D., et al. (2020) Safety and Feasibility of Anti-CD19 CAR T Cells with Fully Human Binding Domains in Patients with B-Cell Lymphoma. Nature Medicine, 26, 270-280. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Heng, G., Jia, J., Li, S., et al. (2020) Sustained Therapeutic Efficacy of Humanized Anti-CD19 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Acute Lymphoblastic Leukemia. Clinical Cancer Research, 26, 1606-1615. [Google Scholar] [CrossRef]
|
|
[14]
|
Wang, Z.Z., et al. (2020) Construction of a New Anti-CD123 Chimeric Antigen Receptor T Cells and Effect of Anti-Acute Myeloid Leukemia. Zhonghua Xue Ye Xue Za Zhi, 41, 192-197.
|
|
[15]
|
Ritchie, D.S., Neeson, P.J., Khot, A., et al. (2013) Persistence and Efficacy of Second Generation CAR T Cell against the LeY Antigen in Acute Myeloid Leukemia. Molecular Therapy, 21, 2122-2129. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
John, S., Chen, H., Deng, M., et al. (2018) A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML. Molecular Therapy, 26, 2487-2495. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Sterner, R.C. and Sterner, R.M. (2021) CAR-T Cell Therapy: Current Limitations and Potential Strategies. Blood Cancer Journal, 11, Article No. 69. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Zhao, L. and Cao, Y.J. (2019) Engineered T Cell Therapy for Cancer in the Clinic. Frontiers in Immunology, 10, 2250. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Blüthmann, H., Kisielow, P., Uematsu, Y., et al. (1988) T-Cell-Specific Deletion of T-Cell Receptor Transgenes Allows Functional Rearrangement of Endogenous Alpha- and Beta-Genes. Nature, 334, 156-159. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Robbins, P.F., Kassim, S.H., Tran, T.L.N., et al. (2015) A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-Cell Receptor: Long-Term Follow-Up and Correlates with Response. Clinical Cancer Research, 21, 1019-1027. [Google Scholar] [CrossRef]
|
|
[21]
|
Galva, L.D.C., Cai, L., Shao, Y., et al. (2020) Engineering T Cells for Immunotherapy of Primary Human Hepatocellular Carcinoma. Journal of Genetics and Genomics, 47, 1-15. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Zhang, J. and Wang, L. (2019) The Emerging World of TCR-T Cell Trials against Cancer: A Systematic Review. Technology in Cancer Research & Treatment, 18, 1533033819831068. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Tawara, I., Kageyama, S., Miyahara, Y., et al. (2017) Safety and Persistence of WT1-Specific T-Cell Receptor Gene-Transduced Lymphocytes in Patients with AML and MDS. Blood, 130, 1985-1994. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Biernacki, M.A., Brault, M. and Bleakley, M. (2019) T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies. The Cancer Journal, 25, 179-190. [Google Scholar] [CrossRef]
|
|
[25]
|
Dossa, R.G., Cunningham, T., Sommermeyer, D., et al. (2018) Development of T-Cell Immunotherapy for Hematopoietic Stem Cell Transplantation Recipients at Risk of Leukemia Relapse. Blood, 131, 108-120. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
叶春梅, 叶韵斌. 实体肿瘤TCR-T治疗研究的现状与面临的挑战[J]. 中国肿瘤生物治疗杂志, 2020, 27(9): 959-967.
|
|
[27]
|
Rohaan, M.W., van den Berg, J.H., Kvistborg, P., et al. (2018) Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Melanoma: A Viable Treatment Option. Journal for ImmunoTherapy of Cancer, 6, 102. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Bai, Y., Zheng, J., Wang, N., et al. (2015) Effects of Dendritic Cell-Activated and Cytokine-Induced Killer Cell Therapy on 22 Children with Acute Myeloid Leukemia after Chemotherapy. Journal of Huazhong University of Science and Technology [Medical Sciences], 35, 689-693. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Rosenberg, S.A., Packard, B.S., Aebersold, P.M., et al. (1988) Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma. A Preliminary Report. The New England Journal of Medicine, 319, 1676-1680. [Google Scholar] [CrossRef]
|
|
[30]
|
梁铭, 张辉, 陈福雄. 肿瘤浸润性淋巴细胞在血液肿瘤中作用的临床研究进展[J]. 中国实验血液学杂志, 2016, 24(4): 1241-1247.
|
|
[31]
|
Coulie, P.G., Van den Eynde, B.J., van der Bruggen, P. and Boon, T. (2014) Tumour Antigens Recognized by T Lymphocytes: At the Core of Cancer Immunotherapy. Nature Reviews Cancer, 14, 135-146. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Chiou, S.-H., Sheu, B.-C., Chang, W.-C., et al. (2005) Current Concepts of Tumor-Infiltrating Lymphocytes in Human Malignancies. Journal of Reproductive Immunology, 67, 35-50. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Leon, E., Ranganathan, R. and Savoldo, B. (2020) Adoptive T Cell Therapy: Boosting the Immune System to Fight Cancer. Seminars in Immunology, 49, 101437. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Gottschalk, S., Edwards, O.L., Sili, U., et al. (2003) Generating CTLs against the Subdominant Epstein-Barr Virus LMP1 Antigen for the Adoptive Immunotherapy of EBV-Associated Malignancies. Blood, 101, 1905-1912. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Bollard, C.M., Gottschalk, S., Torrano, V., et al. (2014) Sustained Complete Responses in Patients with Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins. Journal of Clinical Oncology, 32, 798-808. [Google Scholar] [CrossRef]
|
|
[36]
|
Steinman, R.M. (2012) Decisions about Dendritic Cells: Past, Present, and Future. Annual Review of Immunology, 30, 1-22. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Weinstock, M., Rosenblatt, J. and Avigan, D. (2017) Dendritic Cell Therapies for Hematologic Malignancies. Molecular Therapy—Methods & Clinical Development, 5, 66-75. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Suehiro, Y., Hasegawa, A., Iino, T., et al. (2015) Clinical Outcomes of a Novel Therapeutic Vaccine with Tax Peptide-Pulsed Dendritic Cells for Adult T Cell Leukaemia/Lymphoma in a Pilot Study. British Journal of Haematology, 169, 356-367. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Sabado, R.L., Balan, S. and Bhardwaj, N. (2017) Dendritic Cell-Based Immunotherapy. Cell Research, 27, 74-95. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
王建莉, 路小超, 封贺, 赵同军. 树突状细胞与肿瘤免疫系统相互作用研究进展[J]. 生命科学, 2020, 32(2): 188-194.
|
|
[41]
|
Wang, S., Wang, X., Zhou, X., et al. (2020) DC-CIK as a Widely Applicable Cancer Immunotherapy. Expert Opinion on Biological Therapy, 20, 601-607. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Mosińska, P., Gabryelska, A., Zasada, M., et al. (2017) Dual Functional Capability of Dendritic Cells—Cytokine-Induced Killer Cells in Improving Side Effects of Colorectal Cancer Therapy. Frontiers in Pharmacology, 8, 126. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
时靖, 马甜甜, 刘华胜. 树突状细胞联合细胞因子诱导的杀伤细胞免疫治疗血液系统肿瘤的研究进展[J]. 中国实验血液学杂志, 2018, 26(4): 1235-1239.
|
|
[44]
|
刘华胜, 时靖, 刘海波, 等. 自体DC-CIK细胞联合其它免疫细胞治疗血液系统肿瘤的回顾性研究[J]. 中国实验血液学杂志, 2019, 27(3): 983-990.
|
|
[45]
|
Rezvani, K., Rouce, R., Liu, E. and Shpall, E. (2017) Engineering Natural Killer Cells for Cancer Immunotherapy. Molecular Therapy, 25, 1769-1781. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Geiger, T.L. and Sun, J.C. (2016) Development and Maturation of Natural Killer Cells. Current Opinion in Immunology, 39, 82-89. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Shimasaki, N., Jain, A. and Campana, D. (2020) NK Cells for Cancer Immunotherapy. Nature Reviews Drug Discovery, 19, 200-218. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Romee, R., Rosario, M., Berrien-Elliott, M.M., et al. (2016) Cytokine-Induced Memory-Like Natural Killer Cells Exhibit Enhanced Responses against Myeloid Leukemia. Science Translational Medicine, 8, 357ra123. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Shah, N., Li, L., McCarty, J., et al. (2017) Phase I Study of Cord Blood-Derived Natural Killer Cells Combined with Autologous Stem Cell Transplantation in Multiple Myeloma. British Journal of Haematology, 177, 457-466. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Björklund, A.T., Carlsten, M., Sohlberg, E., et al. (2018) Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML. Clinical Cancer Research, 24, 1834-1844. [Google Scholar] [CrossRef]
|
|
[51]
|
Fang, F., Xiao, W. and Tian, Z. (2017) NK Cell-Based Immunotherapy for Cancer. Seminars in Immunology, 31, 37-54. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Wang, W., Jiang, J. and Wu, C. (2020) CAR-NK for Tumor Immunotherapy: Clinical Transformation and Future Prospects. Cancer Letters, 472, 175-180. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Klingemann, H. (2014) Are Natural Killer Cells Superior CAR Drivers? Oncoimmunology, 3, e28147. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Romanski, A., Uherek, C., Bug, G., et al. (2016) CD19-CAR Engineered NK-92 Cells Are Sufficient to Overcome NK Cell Resistance in B-Cell Malignancies. Journal of Cellular and Molecular Medicine, 20, 1287-1294. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Liu, E., Marin, D., Banerjee, P., et al. (2020) Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. The New England Journal of Medicine, 382, 545-553. [Google Scholar] [CrossRef]
|
|
[56]
|
Tang, X., Yang, L., Li, Z., et al. (2018) First-in-Man Clinical Trial of CAR NK-92 Cells: Safety Test of CD33-CAR NK-92 Cells in Patients with Relapsed and Refractory Acute Myeloid Leukemia. American Journal of Cancer Research, 8, 1083-1089.
|